upadacitinib · Rinvoq

Small molecule

Also known as ABT-494

Approvedregulatory verdict

Evidence outlook

Approved: Atopic Dermatitis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis (label: moderately to severely active UC or CD who have had an inadequate response, lost response or were...), Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Systemic Lupus Erythematosus · Phase 3Vitiligo · Phase 3 · filing submittedHidradenitis Suppurativa · Phase 3Alopecia Areata · Phase 3 · filing submitted

Also approved (11)
US
  • Ankylosing Spondylitis RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.Outside this platform's coverage
  • Non-radiographic Axial Spondyloarthritis RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.
  • Polyarticular Juvenile Idiopathic Arthritis RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an inadequate response or intolerance to one or more TNF blockers.
    Outside this platform's coverage
  • Giant Cell Arteritis RINVOQ is indicated for the treatment of adults with giant cell arteritis.Outside this platform's coverage
Product first approved 2019FDA label
EU
  • Severe alopecia areata in adults and adolescents 12 years and older (Rinvoq)news.abbvie.com
  • Marketing authorisation of Rinvoq (first indication RA); current EU label includes ulcerative colitis and Crohn's diseaseEMA
  • Non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy (Rinvoq)news.abbvie.com
Product first approved 2019
JP
  • Moderately to severely active Crohn's disease with inadequate response to existing therapykyodonewsprwire.jp
  • Moderately to severely active ulcerative colitis with inadequate response to existing therapykyodonewsprwire.jp
Product first approved 2022
UK
  • Moderately to severely active ulcerative colitis and Crohn's disease
Product first approved 2022medicines.org.uk
CA
  • Rheumatoid Arthritis RINVOQ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Psoriatic Arthritis RINVOQ is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs. RINVOQ may be used as monotherapy or in combination with...
Product first approved 2019Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (47)
Alopecia Areata
NCT07772492 · AbbVie
2026-08-24 – 2032-03 · Severe Alopecia Areata
What this study did
Atopic Dermatitis
NCT06389136 · AbbVie
2024-06-14 – 2027-05 · Atopic Dermatitis
What this study did
NCT06390722 · AbbVie
2024-05-23 – 2026-07-08 · Atopic Dermatitis, Sleep Disturbance
What this study did
NCT04195698 · AbbVie
2020-01-15 – 2023-09-11 · Atopic Dermatitis
What this study did
NCT03738397 · AbbVie
2019-02-21 – 2020-12-09 · Atopic Dermatitis
What this study did
Crohn's Disease
NCT06332534 · AbbVie
2024-08-08 – 2031-01 · Crohn's Disease
What this study did
NCT06227910 · Takeda
2025-01-02 – 2028-08-01 · Crohn's Disease
What this study did
NCT07149467 · Sixth Affiliated Hospital, Sun Yat-sen University
2025-09-10 – 2027-12-31 · Crohn's Disease Aggravated, Crohn's Disease in Remission
What this study did
Hidradenitis Suppurativa
Psoriatic Arthritis
Rheumatoid Arthritis
NCT07008846 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2025-05-10 – 2026-09-30 · Moderate to Severe Rheumatoid Arthritis
What this study did
NCT05121298 · Atsushi Kawakami
2021-01-12 – 2024-09-30 · Rheumatoid Arthritis, JAK Inhibitor, Musculoskeletal Ultrasound, Biomarker
What this study did
Systemic Lupus Erythematosus
Ulcerative Colitis
NCT06660693 · McMaster University
2025-04-16 – 2027-09 · Colitis, Ulcerative
What this study did
NCT03006068 · AbbVie
2017-01-31 – 2027-07 · Ulcerative Colitis (UC)
What this study did
Vitiligo
NCT07896434 · AbbVie
2027-01-28 – 2032-08 · Non-Segmental Vitiligo
What this study did
NCT06118411 · AbbVie
2023-12-19 – 2028-03 · Vitiligo
What this study did
Other / comorbidity
NCT04161898 · AbbVie
2020-02-04 – 2028-08 · Takayasu Arteritis (TAK)
What this study did
NCT06928272 · Douglas D. Fraser
2025-09-10 – 2027-12 · Long COVID
What this study did
NCT03725202 · AbbVie
2019-01-24 – 2025-03-11 · Giant Cell Arteritis (GCA)
What this study did
NCT04169373 · AbbVie
2019-11-26 – 2025-02-28 · Spondyloarthritis
What this study did
NCT06758947 · Assiut University
2023-01-15 – 2024-11-15 · Interstitial Lung Disease Due to Systemic Disease (Disorder)
What this study did
Phase 2/3 (3)
Phase 2 (21)
Atopic Dermatitis
NCT07678645 · RenJi Hospital
2026-06-01 – 2028-05-31 · Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Atopic Dermatitis (AD)
What this study did
NCT02925117 · AbbVie
2016-10-25 – 2019-01-31 · Atopic Dermatitis
What this study did
Crohn's Disease
Hidradenitis Suppurativa
NCT07727889 · Peking Union Medical College
2026-07-01 – 2027-07-01 · Hidradenitis Suppurativa (Acne Inversa)
What this study did
Rheumatoid Arthritis
NCT02049138 · AbbVie
2014-01-24 – 2021-07-29 · Rheumatoid Arthritis
What this study did
NCT03823378 · AbbVie
2019-05-13 – 2020-09-09 · Rheumatoid Arthritis (RA)
What this study did
Systemic Lupus Erythematosus
Vitiligo
NCT04927975 · AbbVie
2021-06-30 – 2023-08-29 · Non-Segmental Vitiligo
What this study did
Other / comorbidity
NCT07588568 · University of North Carolina, Chapel Hill
2026-09-30 – 2030-06 · EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
What this study did
NCT07492251 · Centre Hospitalier Universitaire de Nice
2026-10-01 – 2028-11-01 · Lichen Penis Planus
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT07064889 · Peking University People's Hospital
2025-07-30 – 2027-12-30 · Immune Thrombocytopenia
What this study did
NCT06862284 · Peking University People's Hospital
2025-03-10 – 2027-08-31 · Primary Sjögren's Syndrome (pSS)
What this study did
NCT07080346 · Liu Tian
2024-01-25 – 2025-07-08 · Behcet Syndrome
What this study did
NCT03178487 · AbbVie
2017-10-24 – 2022-02-17 · Ankylosing Spondylitis (AS)
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT07670156 · Lisa Satter
2026-12 – 2028-08 · JAK1 GOF, STAT1 GOF, STAT3 GOF, STAT5B GOF, STAT6 GOF
What this study did
NCT06873100 · Peking University People's Hospital
2024-11-15 – 2026-12-31 · Relapsing Polychondritis
What this study did
Phase 1 (8)
Atopic Dermatitis
NCT03646604 · AbbVie
2019-01-31 – 2024-08-29 · Atopic Dermatitis
What this study did
Crohn's Disease
NCT06902987 · Sixth Affiliated Hospital, Sun Yat-sen University
2024-01-17 – 2026-12-30 · Crohn's Diseases, Active Anal Fistula, Upadacitinib
What this study did
Rheumatoid Arthritis
NCT01741493 · AbbVie (prior sponsor, Abbott)
2012-11 – 2013-12 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03725007 · AbbVie
2019-06-24 – 2029-03 · Juvenile Idiopathic Arthritis (JIA)
What this study did
NCT06684522 · Northwestern University
2025-12-18 – 2027-06 · Eyelid Dermatitis
What this study did
NCT07843693 · AbbVie
2026-08-26 – 2026-12 · Healthy Volunteers
What this study did
NCT07425899 · AbbVie
2026-02-26 – 2026-06-05 · Healthy Volunteer
What this study did
NCT06379958 · Modern Biosciences Ltd
2024-04-08 – 2024-09-30 · Pharmacokinetics
What this study did
Phase 4 (19)
Atopic Dermatitis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
Crohn's Disease
NCT07510191 · Sixth Affiliated Hospital, Sun Yat-sen University
2026-03-01 – 2029-12-31 · Crohn Disease (CD)
What this study did
NCT06520397 · Sixth Affiliated Hospital, Sun Yat-sen University
2024-07-15 – 2027-07-31 · Crohn Disease
What this study did
Psoriatic Arthritis
NCT06454188 · CARE ARTHRITIS LTD.
2024-12-03 – 2028-10 · Psoriatic Arthritis, Spondyloarthritis, Axial
What this study did
Rheumatoid Arthritis
NCT06687551 · University Hospital, Toulouse
2025-06-06 – 2029-04-01 · Rheumatoid Arthritis (RA
What this study did
NCT07636057 · Sheikh Zayed Federal Postgraduate Medical Institute
2026-07-05 – 2027-05-10 · Rheumatoid Arthritis (RA)
What this study did
NCT05080218 · Jeffrey Curtis
2021-11-15 – 2024-05-28 · Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
What this study did
Ulcerative Colitis
NCT07258771 · Berinstein, Jeffrey
2026-01-16 – 2030-12 · Ulcerative Colitis Acute
What this study did
NCT07700446 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2026-11-15 – 2030-04 · Ulcerative Colitis (UC)
What this study did
NCT07502339 · University of California, San Francisco
2026-10-15 – 2028-12-01 · UC - Ulcerative Colitis
What this study did
NCT07550673 · Xijing Hospital of Digestive Diseases
2026-04-20 – 2028-11-01 · Acute Severe Ulcerative Colitis
What this study did
NCT05867329 · Berinstein, Jeffrey
2023-09-30 – 2027-11 · Ulcerative Colitis Acute
What this study did
NCT07546097 · Yongquan Shi
2026-03-23 – 2027-06-30 · Acute Severe Ulcerative Colitis
What this study did
Other / comorbidity
NCT07770646 · The University of Texas Health Science Center, Houston
2026-11-01 – 2029-09-15 · Axial Spondyloarthritis (AxSpA)
What this study did
NCT07773623 · Tianjin Medical University
2025-01-01 – 2027-12-31 · Uveitis
What this study did
NCT07018206 · CARE ARTHRITIS LTD.
2026-05 – 2027-05 · Axial Spondylarthritis (axSpA)
What this study did
NCT06773403 · Psoriasis Treatment Center of Central New Jersey
2024-04-09 – 2025-06-06 · Prurigo Nodularis
What this study did
Early phase / not applicable (2)
Ulcerative Colitis
NCT06095596 · Sixth Affiliated Hospital, Sun Yat-sen University
2023-11-01 – 2026-10-31 · Ulcerative Colitis (UC)
What this study did
Vitiligo
NCT06454461 · Jilin University
2024-12-04 – 2029-06-01 · Vitiligo
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Rheumatoid Arthritis
NCT07904754 · AbbVie
2026-12-07 – 2029-07 · Rheumatoid Arthritis
What this study did

Competitive landscape

This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Atopic Dermatitis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Upadacitinib (Rinvoq): this drugApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03607422: EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo).
NCT03569293: EASI-75 at week 16 (Measure Up 1): 70% (196/281) upadacitinib 15mg, 80% (227/285) upadacitinib 30mg, vs 16% (46/281) placebo; adjusted difference vs placebo 53.3% [46.4-60.2] and 63.4% [57.1-69.8] respectively, both p<0.0001
Abrocitinib (Cibinqo)ApprovedSmall moleculeJAK1Reliable signal
NCT04345367: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30)
NCT03349060: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12 (Baseline, Week 12): PF-04965842 100 mg 23.7% | PF-04965842 200 mg 43.8% vs Placebo 7.9%
Crisaborole (Eucrisa)ApprovedSmall moleculePDE4Reliable signal
NCT02118766: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4%
NCT02118792: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 (Day 29): AN2728 Ointment, 2 Percent (%) 31.4% vs AN2728 Ointment, Vehicle 18%
Difamilast (Moizerto / Adquey)ApprovedSmall moleculePDE4Partial signal
NCT03908970: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36)
NCT03911401: IGA success (score 0 or 1 with at least a 2-grade improvement) at week 4: difamilast 0.3% 44.6% and 1% 47.1% vs vehicle 18.1%; p<0.001 for each dose vs vehicle. n=83, 85, 83 (Saeki 2022, Br J Dermatol).
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaWeak signal
NCT04417894: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7%
NCT03345914: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4%
Lebrikizumab (Ebglyss)ApprovedMonoclonal antibodyIL-13Reliable signal
NCT04178967: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9)
NCT04146363: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 43.1% (95% CI 37.1 to 49) vs Placebo 12.7% (95% CI 7 to 18.5)
Nemolizumab (Nemluvio)ApprovedMonoclonal antibodyIL-31 receptor AReliable signal
NCT03989349: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 37.7% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 26%
NCT03985943: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 35.6% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 24.6%
Roflumilast (Zoryve)ApprovedSmall moleculePDE4Reliable signal
NCT06631170: Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001)
NCT04773600: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 (Week 4): Roflumilast Cream 0.15% 28.9% vs Vehicle Cream 12%
Ruxolitinib (Opzelura)ApprovedSmall moleculeJAK1/2Reliable signal
NCT03745638: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5)
NCT03745651: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 39% (95% CI 32.6 to 45.6) | VC Period: Ruxolitinib 1.5% Cream BID 51.3% (95% CI 44.6 to 58) vs VC Period: Vehicle Cream BID 7.6% (95% CI 3.5 to 14)
TapinarofApprovedSmall moleculeAryl hydrocarbon receptor, Aryl Hydrocarbon Receptor AgonistReliable signal
NCT05014568: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 45.4% vs Vehicle Cream 13.9%
NCT05032859: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 46.4% vs Vehicle Cream 18%
Tralokinumab (Adbry)ApprovedMonoclonal antibodyIL-13Reliable signal
NCT05958407: Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9)
ADSTEMPhase 3Cell therapyautologous adipose-derived mesenchymal stem cell (AD-MSC) therapynot yet gradedNo reviewed efficacy summary in this indication
AsivatrepPhase 3Small moleculeTRPV1Reliable signal
NCT02965118: IGA success (score 0 or 1) at week 8: 36.0% asivatrep vs 12.8% vehicle (P<.001)
Baricitinib (Olumiant)Phase 3Small moleculeJAK, JAK1/2Reliable signal
NCT03334422: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5%
NCT03334396: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) (16 Weeks): 2 mg Baricitinib 11.4% | 4 mg Baricitinib 16.8% vs Placebo 4.8%
GS101Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Ivarmacitinib
Phase 3(overall)
Small moleculeJAK
not yet graded(overall)
No reviewed efficacy summary in this indication
Jaktinib (Zepuping)Phase 3Small moleculeJAK1/2/3Partial signalNo reviewed efficacy summary in this indication
LW402Phase 3Small moleculeJAK1Partial signalNo reviewed efficacy summary in this indication
ManfidokimabPhase 3Monoclonal antibodyIL-4R-alphaPartial signalNo reviewed efficacy summary in this indication
PumecitinibPhase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
QL2108Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
QLM3003Phase 3Small moleculeJAKPartial signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphaPartial signal
NCT05017480: vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026).
RezpegaldesleukinPhase 3Protein / enzyme therapeuticIL-2 mutein (Treg-selective)not yet gradedNo reviewed efficacy summary in this indication
SHR-1819Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Soficitinib (ICP-332)Phase 3Small moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
SSGJ-611Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
StapokibartPhase 3Monoclonal antibodyIL-4R-alphaReliable signal
NCT06277765: EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001)
NCT05265923: EASI-75 response at week 16: 66.9% stapokibart vs 25.8% placebo (significantly higher)
TelikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VC005Phase 3Small moleculeJAK1, JAK1not yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1Reliable signal
NCT06277245: EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001)
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
BarzolvolimabPhase 2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
BempikibartPhase 2Monoclonal antibodyIL-7 receptor alphanot yet gradedNo reviewed efficacy summary in this indication
BFB759Phase 2Monoclonal antibodyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
BosakitugPhase 2Monoclonal antibodyTSLPWeak signal
NCT05932654: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 (Week 26): 300 mg 94.1% (95% CI 71.3 to 99.9)
CamoteskimabPhase 2Monoclonal antibodyIL-18Partial signalNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13Weak signalFeatured results are safety only in this race
CMS-D001Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—Weak signalFeatured results are safety only in this race
EVO101Phase 2Small moleculeIRAK4Partial signal
NCT05579899: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) missed
EVO301Phase 2Protein / enzyme therapeuticIL-18Partial signal
NCT06723405: Placebo-adjusted improvement in EASI at Week 12: 33% (95% CI -50, -17; p<0.01)
FB825Phase 2Monoclonal antibodyCεmX domain of membrane-bound IgE (mIgE)Weak signalNo reviewed efficacy summary in this indication
FelcorekibartPhase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
GalvokimigPhase 2Multispecific antibodyIL-13, IL-17A, IL-17FPartial signalFeatured results are safety only in this race
GHZ339Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
GIA632Phase 2Monoclonal antibodyIL-15not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 2Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
HY209gelPhase 2Small moleculeGPCR19 / GPBAR1 (TGR5, bile acid receptor)Partial signalFeatured results are safety only in this race
IN-115314Phase 2Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
JNJ-95597528Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
JYP0061Phase 2Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6Weak signalFeatured results are safety only in this race
LepzacitinibPhase 2Small moleculeJAK1/JAK3not yet gradedNo reviewed efficacy summary in this indication
LNK01004Phase 2Small moleculePan-JAKPartial signalFeatured results are safety only in this race
LT-002-158Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
ModzatinibPhase 2Small moleculeITK and JAK3not yet gradedNo reviewed efficacy summary in this indication
MosedipimodPhase 2Small moleculeNF-kB / CCL26 pathwaynot yet gradedNo reviewed efficacy summary in this indication
Nitrosomonas Eutropha (B244)Phase 2Microbiome therapeuticlive biotherapeutic (topical ammonia-oxidizing bacterium, AOBiome/B244)Reliable signal
NCT04490109: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) (Baseline to Day 28): B244 O.D. 5.0 -2.8 score on a scale (Standard Error 0.184) | B244 O.D. 20.0 -2.8 score on a scale (Standard Error 0.184) vs Vehicle -2.1 score on a scale (Standard Error 0.18)
OlevaprubartPhase 2Monoclonal antibodyOX40Weak signalFeatured results are safety only in this race
OmpekimigPhase 2Multispecific antibodyIL-4, IL-13, IL-33Partial signal
NCT05995964: Stage 1, high-dose ompekimig vs placebo: met the primary endpoint (EASI-75 at week 16); no ompekimig figures were given (2026-03-09).
OpSCFPhase 2Monoclonal antibodyStem cell factor (SCF / KIT ligand)Partial signal
NCT06101823: Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 16 (Baseline, Week 16): OpSCF 600 mg -71.476 percent change (Standard Error 8.6876) | OpSCF Matching-Placebo -50.992 percent change (Standard Error 8.8073)
OrismilastPhase 2Small moleculePDE4B/DPartial signal
NCT05469464: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 (Baseline and Week 16): Orismilast Modified Release Tablets 20 mg BID -55.1% (Standard Error 4.89) | Orismilast Modified Release Tablets 30 mg BID -52.2% (Standard Error 5.39) | Orismilast Modified Release Tablets 40 mg BID -61.4% (Standard Error 5.02) vs Placebo Tablets BID -50.4% (Standard Error 4.98) missed
NCT02496546: In adults with mild to moderate atopic dermatitis treated twice daily for 3 weeks, total sign score at end of treatment was 5.2 (least squares mean 5.1) with orismilast cream 20 mg/g versus 6.2 (LS mean 6.3) with vehicle, a statistically significant difference (P = .014).
PF-08049820Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
PUR 0110Phase 2——not yet gradedNo reviewed efficacy summary in this indication
QLS12010Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
ZL-82Phase 2Small moleculeJAKnot yet gradedNo reviewed efficacy summary in this indication
AZD0449
Phase 1(overall)
—JAK1
Partial signal(overall)
No reviewed efficacy summary in this indication
LPX-TI641Phase 1Small moleculeTIM receptor (Treg-expanding)not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication
Londamocitinib
Discontinued
Small moleculeJAK1
Partial signal(overall)
No reviewed efficacy summary in this indication
TipasertidegDiscontinuedSmall moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 75 furthest-along competitors are listed; 40 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(47 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rinvoq (upadacitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (1)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2026-11 · NCT06389136 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2026-12 · NCT07843693 · CT.gov ↗
What to watch
Phase 3Long COVIDRecruiting
Est. primary completion 2026-12 · NCT06928272 · CT.gov ↗
What to watch
Phase 2Primary Sjögren's Syndrome (pSS)Not yet recruiting
Est. primary completion 2026-12-30 · NCT06862284 · CT.gov ↗
What to watch
Phase 3Crohn's DiseaseNot yet recruiting
Est. primary completion 2026-12-31 · NCT07149467 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06520397 · CT.gov ↗
What to watch
2027 (15)
January 2027 (1)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2027-01 · NCT06701331 · CT.gov ↗
What to watch
March 2027 (3)
Phase 3Systemic Lupus ErythematosusActive not recruiting
Est. primary completion 2027-03 · NCT05843643 · CT.gov ↗
What to watch
Phase 4Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2027-03-05 · NCT07636057 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2027-03-30 · NCT07546097 · CT.gov ↗
What to watch
May 2027 (2)
Phase 3Ulcerative ColitisRecruiting
Est. primary completion 2027-05 · NCT06660693 · CT.gov ↗
What to watch
Phase 4Axial Spondylarthritis (axSpA)Not yet recruiting
Est. primary completion 2027-05 · NCT07018206 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1Eyelid DermatitisRecruiting
Est. primary completion 2027-06 · NCT06684522 · CT.gov ↗
What to watch
Phase 3Crohn's DiseaseRecruiting
Est. primary completion 2027-06-08 · NCT06227910 · CT.gov ↗
What to watch
July 2027 (3)
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-07 · NCT03006068 · CT.gov ↗
What to watch
Phase 2Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2027-07-01 · NCT07727889 · CT.gov ↗
What to watch
Phase 2Immune ThrombocytopeniaNot yet recruiting
Est. primary completion 2027-07-30 · NCT07064889 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2027-09 · NCT03345823 · CT.gov ↗
What to watch
November 2027 (2)
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2027-11 · NCT05867329 · CT.gov ↗
What to watch
Phase 2Atopic DermatitisNot yet recruiting
Est. primary completion 2027-11-30 · NCT07678645 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4UveitisActive not recruiting
Est. primary completion 2027-12-31 · NCT07773623 · CT.gov ↗
What to watch
2028 (13)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3VitiligoActive not recruiting
Est. primary completion 2028-03 · NCT06118411 · CT.gov ↗
What to watch
April 2028 (1)
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2028-04-01 · NCT07550673 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Lichen Penis PlanusRecruiting
Est. primary completion 2028-05-01 · NCT07492251 · CT.gov ↗
What to watch
August 2028 (4)
Phase 1/2JAK1 GOF, STAT1 GOF, STAT3 GOF, STAT5B GOF, STAT6 GOFNot yet recruiting
Est. primary completion 2028-08 · NCT07670156 · CT.gov ↗
What to watch
Phase 3Takayasu Arteritis (TAK)Active not recruiting
Est. primary completion 2028-08 · NCT04161898 · CT.gov ↗
What to watch
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2028-08 · NCT05782907 · CT.gov ↗
What to watch
Phase 3Hidradenitis SuppurativaActive not recruiting
Est. primary completion 2028-08 · NCT05889182 · CT.gov ↗
What to watch
September 2028 (2)
Phase 4Psoriatic ArthritisRecruiting
Est. primary completion 2028-09 · NCT06454188 · CT.gov ↗
What to watch
Phase 4Axial Spondyloarthritis (AxSpA)Not yet recruiting
Est. primary completion 2028-09-15 · NCT07770646 · CT.gov ↗
What to watch
December 2028 (3)
Phase 1Juvenile Idiopathic Arthritis (JIA)Active not recruiting
Est. primary completion 2028-12 · NCT03725007 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisNot yet recruiting
Est. primary completion 2028-12-01 · NCT07502339 · CT.gov ↗
What to watch
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2028-12-31 · NCT07510191 · CT.gov ↗
What to watch
2029 (6)
February 2029 (1)
Phase 3Alopecia AreataActive not recruiting
Est. primary completion 2029-02 · NCT07023302 · CT.gov ↗
What to watch
April 2029 (1)
Phase 4Rheumatoid ArthritisRecruiting
Est. primary completion 2029-04-01 · NCT06687551 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Juvenile Idiopathic ArthritisRecruiting
Est. primary completion 2029-06 · NCT05609630 · CT.gov ↗
What to watch
November 2029 (2)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2029-11 · NCT06461897 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisNot yet recruiting
Est. primary completion 2029-11 · NCT07700446 · CT.gov ↗
What to watch
December 2029 (1)
Phase 4Ulcerative ColitisRecruiting
Est. primary completion 2029-12 · NCT07258771 · CT.gov ↗
What to watch
2030 (3)
February 2030 (1)
Phase 2EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)Recruiting
Est. primary completion 2030-02 · NCT07588568 · CT.gov ↗
What to watch
April 2030 (1)
Phase 3Alopecia AreataRecruiting
Est. primary completion 2030-04 · NCT06012240 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4Atopic DermatitisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Phase 3Crohn's DiseaseActive not recruiting
Est. primary completion 2031-01 · NCT06332534 · CT.gov ↗
What to watch
2032 (2)
March 2032 (1)
Phase 3Alopecia AreataRecruiting
Est. primary completion 2032-03 · NCT07772492 · CT.gov ↗
What to watch
August 2032 (1)
Phase 3VitiligoNot yet recruiting
Est. primary completion 2032-08 · NCT07896434 · CT.gov ↗
What to watch
2035 (1)
June 2035 (1)
Phase 2/3Systemic SclerosisNot yet recruiting
Est. primary completion 2035-06 · NCT07933211 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(10)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026ApprovalEuropean Commission approves Rinvoq for polyarticular juvenile idiopathic arthritis
EU, EC · AbbVie · Source ↗
29 July 2026ApprovalEuropean Commission approves Rinvoq in severe alopecia areata
EU, EC · Source ↗
28 April 2026Filing submittedAbbVie submits a US application for upadacitinib (RINVOQ) in severe alopecia areata
US, FDA · AbbVie · Source ↗
3 February 2026Filing submittedAbbVie submits US and EU applications for upadacitinib (Rinvoq) in vitiligo
US, FDA · AbbVie · Source ↗
29 October 2025Topline resultTwo Phase 3 studies of upadacitinib in non-segmental vitiligo met their co-primary endpoints
AbbVie · Source ↗
13 October 2025ApprovalFDA approves updated RINVOQ indication for UC and Crohn's disease
US, FDA · Source ↗
21 August 2025Topline resultPhase 3 UP-AA Study 1 of upadacitinib in alopecia areata met its primary endpoint
AbbVie · Source ↗
30 July 2025Topline resultPhase 3 UP-AA Study 2 of upadacitinib in alopecia areata met its primary endpoint
AbbVie · Source ↗
29 April 2025ApprovalFDA approves RINVOQ for giant cell arteritis
US, FDA · Source ↗
8 April 2025ApprovalEC approves RINVOQ for giant cell arteritis
EU, EC · Source ↗